Cara Therapeutics Sees Unusually High Options Volume (CARA)


Cara Therapeutics (NASDAQ:CARA) saw unusually large options trading on Thursday. Traders bought 6,902 call options on the company. This is an increase of 985% compared to the typical daily volume of 636 call options.

A number of research firms recently commented on CARA. HC Wainwright set a $22.00 price target on Cara Therapeutics and gave the stock a “buy” rating in a report on Monday, March 19th. Stifel Nicolaus upped their price objective on Cara Therapeutics to $20.00 and gave the stock a “buy” rating in a report on Wednesday. Janney Montgomery Scott raised Cara Therapeutics from a “neutral” rating to a “buy” rating and decreased their price objective for the stock from $27.00 to $21.00 in a report on Monday, February 12th. BidaskClub cut Cara Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, March 20th. Finally, Zacks Investment Research raised Cara Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, March 21st. Two equities research analysts have rated the stock with a sell rating, three have issued a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company’s stock. Cara Therapeutics has a consensus rating of “Buy” and an average price target of $24.37.


Get Cara Therapeutics alerts:

Large investors have recently added to or reduced their stakes in the stock. Goldman Sachs Group Inc. raised its holdings in Cara Therapeutics by 732.3% during the 4th quarter. Goldman Sachs Group Inc. now owns 78,811 shares of the biopharmaceutical company’s stock valued at $964,000 after buying an additional 91,275 shares during the period. Disciplined Growth Investors Inc. MN raised its holdings in Cara Therapeutics by 1.4% during the 4th quarter. Disciplined Growth Investors Inc. MN now owns 861,219 shares of the biopharmaceutical company’s stock valued at $10,541,000 after buying an additional 12,069 shares during the period. MANA Advisors LLC purchased a new stake in Cara Therapeutics during the 4th quarter valued at $125,000. Cetera Advisor Networks LLC purchased a new stake in Cara Therapeutics during the 4th quarter valued at $125,000. Finally, Virtus Fund Advisers LLC purchased a new stake in Cara Therapeutics during the 4th quarter valued at $338,000. Institutional investors own 54.43% of the company’s stock.


Shares of CARA opened at $15.56 on Friday. The company has a market cap of $541.51 million, a PE ratio of -8.37 and a beta of 2.96. Cara Therapeutics has a 1 year low of $11.11 and a 1 year high of $28.50.

Cara Therapeutics (NASDAQ:CARA) last released its quarterly earnings results on Wednesday, May 9th. The biopharmaceutical company reported ($0.51) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.47) by ($0.04). equities research analysts predict that Cara Therapeutics will post -2.16 earnings per share for the current fiscal year.

About Cara Therapeutics

Cara Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities designed to alleviate pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells.

Leave a Reply

Your email address will not be published. Required fields are marked *